A Study to Evaluate The Impact on Skin Quality Attributes by Juvederm® Volite Injection on Healthy Volunteers
- Conditions
- Interventions
- First Posted Date
- 2019-12-20
- Last Posted Date
- 2021-08-26
- Lead Sponsor
- Allergan
- Target Recruit Count
- 11
- Registration Number
- NCT04206293
- Locations
- 🇵🇱
EuroFins Dermscan Poland, Gdansk, Poland
Safety, Tolerability and Drug- Drug Interaction Study of Ubrogepant With Erenumab or Galcanezumab in Participants With Migraine
- First Posted Date
- 2019-11-27
- Last Posted Date
- 2021-03-10
- Lead Sponsor
- Allergan
- Target Recruit Count
- 40
- Registration Number
- NCT04179474
- Locations
- 🇺🇸
Spaulding, West Bend, Wisconsin, United States
🇺🇸QPS, Springfield, Missouri, United States
CoolSculpting® the Upper Arms and Inner Thighs in Participants of Chinese Descent (XinCOOL)
- First Posted Date
- 2019-10-29
- Last Posted Date
- 2021-04-01
- Lead Sponsor
- Allergan
- Target Recruit Count
- 50
- Registration Number
- NCT04142450
- Locations
- 🇨🇦
Pacific Derm, Vancouver, British Columbia, Canada
🇨🇦Vancouver Laser and Skin Care Clinic, Vancouver, British Columbia, Canada
🇨🇦Project Skin MD, Vancouver, British Columbia, Canada
A Study of Armour® Thyroid Compared to Synthetic T4 (Levothyroxine) in Previously Hypothyroid Participants
- Conditions
- Interventions
- First Posted Date
- 2019-10-11
- Last Posted Date
- 2024-06-05
- Lead Sponsor
- Allergan
- Target Recruit Count
- 284
- Registration Number
- NCT04124705
- Locations
- 🇺🇸
Sponsor Site /ID# 235853, Fort Lauderdale, Florida, United States
🇺🇸Sponsor Site /ID# 236809, West Palm Beach, Florida, United States
🇺🇸Sponsor Site /ID# 235032, Atlanta, Georgia, United States
Linaclotide Safety and Efficacy in 2 to 5-Year-Old Participants With Functional Constipation
- First Posted Date
- 2019-10-01
- Last Posted Date
- 2022-04-26
- Lead Sponsor
- Allergan
- Target Recruit Count
- 35
- Registration Number
- NCT04110145
- Locations
- 🇺🇸
HealthStar Research, Hot Springs, Arkansas, United States
🇺🇸Foundation Pediatrics Med Clinical Research Partners, LLC, East Orange, New Jersey, United States
🇺🇸David M. Headley, MD, P.A., Port Gibson, Mississippi, United States
AGN-151586 Dose-Ranging Study for Treatment of Glabellar Lines
- First Posted Date
- 2019-09-19
- Last Posted Date
- 2023-07-28
- Lead Sponsor
- Allergan
- Target Recruit Count
- 198
- Registration Number
- NCT04096326
- Locations
- 🇺🇸
DermResearch Inc. /ID# 234483, Austin, Texas, United States
🇺🇸Austin Institute for Clinical Research /ID# 237135, Pflugerville, Texas, United States
🇺🇸Center for Dermatology Clinical Research /ID# 237798, Fremont, California, United States
BOTOX® Treatment for Adults With a Wide Lower Face Due to Masseter Muscle Prominence
- Conditions
- Interventions
- First Posted Date
- 2019-08-29
- Last Posted Date
- 2023-10-17
- Lead Sponsor
- Allergan
- Target Recruit Count
- 376
- Registration Number
- NCT04073303
- Locations
- 🇨🇦
Project Skin MD LTD /ID# 232763, Vancouver, British Columbia, Canada
🇨🇦Pacific Derm /ID# 233156, Vancouver, British Columbia, Canada
🇨🇦Beacon Dermatology Inc /ID# 233018, Calgary, Alberta, Canada
A Study of the Drugs AGN-242428 and AGN-231868 in Participants With Dry Eye Disease
- Conditions
- Interventions
- First Posted Date
- 2019-07-24
- Last Posted Date
- 2023-03-20
- Lead Sponsor
- Allergan
- Target Recruit Count
- 292
- Registration Number
- NCT04030962
- Locations
- 🇺🇸
Piedmont Eye Center /ID# 232698, Lynchburg, Virginia, United States
🇺🇸Cornea and Cataract Consultants of Arizona /ID# 232769, Phoenix, Arizona, United States
🇺🇸Total Eye Care, PA /ID# 232657, Memphis, Tennessee, United States
A Study to Evaluate the Effectiveness and Safety of OZURDEX® in Patients With Diabetic Macular Edema But Never Treated
- Conditions
- Interventions
- First Posted Date
- 2019-05-17
- Last Posted Date
- 2022-10-07
- Lead Sponsor
- Allergan
- Target Recruit Count
- 82
- Registration Number
- NCT03953807
- Locations
- 🇵🇹
Chuc /Id# 233643, Coimbra, Portugal
🇵🇹IRL - Instituto de Retina e Diabetes Ocular de Lisboa /ID# 233667, Lisbon, Portugal
🇵🇹Hospital de Santo Andre /ID# 233670, Leiria, Portugal
Extension Study to Evaluate the Long-Term Safety and Tolerability of Oral Atogepant for the Prevention of Migraine in Participants With Episodic Migraine
- First Posted Date
- 2019-05-06
- Last Posted Date
- 2022-05-12
- Lead Sponsor
- Allergan
- Target Recruit Count
- 685
- Registration Number
- NCT03939312
- Locations
- 🇺🇸
Pediatric and Adolescent NeuroDevelopmental Associates (PANDA) Neurology, Atlanta, Georgia, United States
🇺🇸Preferred Primary Care Physicians, Pittsburgh, Pennsylvania, United States
🇺🇸Neuro Pain Medical Center, Fresno, California, United States